NEW YORK (Standard&Poor's) April 6, 2009--Standard&Poor's Ratings Services said today that the revised marketing agreement between New York, N.Y.-based Bristol-Myers Squibb Co. and Otsuka Pharmaceutical Co., Ltd. that extends Bristol-Myers U.S. co-promotion rights for Abilify beyond the original 2012 termination, to 2015. This treatment for a variety of psychiatric disorders is Bristol-Myers' second largest selling product, generating $2.15 billion in 2008 revenues, a level 30% above 2007. Without this extension, the loss of these revenues would have occurred the year following the loss of patent protection for Bristol-Myers' largest selling product Plavix. The new agreement increases partner Otsuka's share of U.S. sales to 50% from 35%. In addition, Bristol-Myers will pay about $400 million, a small
